From a regulatory standpoint (according to the SPA), statistical superiority of AXR-07 versus each of its constituent drugs is needed only on the 24-hour (secondary) endpoint, as you note. Nevertheless, I contend that failing to show statig superiority to either or both constituent drugs on the 2-hour (co-primary) endpoints will cause the trial to be considered less than an unqualified success.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.